Shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA - Get Free Report) traded down 0% during mid-day trading on Friday . The stock traded as low as $10.51 and last traded at $10.5150. 25 shares traded hands during trading, a decline of 100% from the average session volume of 68,320 shares. The stock had previously closed at $10.52.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Drugs Made In America Acquisition in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Sell".
Check Out Our Latest Analysis on DMAA
Drugs Made In America Acquisition Stock Performance
The company's 50 day moving average price is $10.47 and its 200-day moving average price is $10.39.
Hedge Funds Weigh In On Drugs Made In America Acquisition
Hedge funds have recently bought and sold shares of the company. Quarry LP bought a new position in Drugs Made In America Acquisition during the third quarter worth $161,000. Sandia Investment Management LP bought a new position in Drugs Made In America Acquisition during the third quarter worth $161,000. Lineage Point Capital LP bought a new position in Drugs Made In America Acquisition during the fourth quarter worth $330,000. JPMorgan Chase & Co. bought a new position in Drugs Made In America Acquisition during the third quarter worth $1,024,000. Finally, Shaolin Capital Management LLC bought a new position in Drugs Made In America Acquisition during the second quarter worth $1,020,000.
About Drugs Made In America Acquisition
(
Get Free Report)
Drugs Made In America Acquisition Corp NASDAQ: DMAA is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company's stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.
Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Drugs Made In America Acquisition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Drugs Made In America Acquisition wasn't on the list.
While Drugs Made In America Acquisition currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
